Fromm M F, Kim R B, Stein C M, Wilkinson G R, Roden D M
Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232-6602, USA.
Circulation. 1999 Feb 2;99(4):552-7. doi: 10.1161/01.cir.99.4.552.
Although quinidine is known to elevate plasma digoxin concentrations, the mechanism underlying this interaction is not fully understood. Digoxin is not extensively metabolized, but it is known to be transported by the drug efflux pump P-glycoprotein, which is expressed in excretory tissues (kidney, liver, intestine) and at the blood-brain barrier. Accordingly, we tested the hypothesis that inhibition of P-glycoprotein-mediated digoxin transport by quinidine contributes to the digoxin-quinidine interaction.
First, we demonstrated active transcellular transport of both digoxin and quinidine in cultured cell lines that express P-glycoprotein in a polarized fashion. In addition, 5 micromol/L quinidine inhibited P-glycoprotein-mediated digoxin transport by 57%. Second, the effect of quinidine on digoxin disposition was studied in wild-type and in mdr1a(-/-) mice, in which the gene expressing the major digoxin-transporting P-glycoprotein has been disrupted. Because the in vitro data showed that quinidine itself is a P-glycoprotein substrate, quinidine doses were reduced in mdr1a(-/-) mice to produce plasma concentrations similar to those in wild-type control animals. Quinidine increased plasma digoxin concentrations by 73.0% (P=0.05) in wild-type animals, compared with 19.5% (P=NS) in mdr1a(-/-) mice. Moreover, quinidine increased digoxin brain concentrations by 73.2% (P=0.05) in wild-type animals; by contrast, quinidine did not increase digoxin brain concentrations in mdr1a(-/-) mice but rather decreased them (-30.7%, P<0.01).
Quinidine and digoxin are both substrates for P-glycoprotein, and quinidine is a potent inhibitor of digoxin transport in vitro. The in vivo data strongly support the hypothesis that inhibition of P-glycoprotein-mediated digoxin elimination plays an important role in the increase of plasma digoxin concentration occurring with quinidine coadministration in wild-type mice and thus support a similar mechanism in humans.
尽管已知奎尼丁可提高血浆地高辛浓度,但这种相互作用的潜在机制尚未完全明确。地高辛代谢不广泛,但已知其通过药物外排泵P-糖蛋白转运,P-糖蛋白在排泄组织(肾脏、肝脏、肠道)及血脑屏障中表达。因此,我们检验了如下假设:奎尼丁对P-糖蛋白介导的地高辛转运的抑制作用导致了地高辛与奎尼丁之间的相互作用。
首先,我们在以极化方式表达P-糖蛋白的培养细胞系中证实了地高辛和奎尼丁的主动跨细胞转运。此外,5 μmol/L奎尼丁使P-糖蛋白介导的地高辛转运抑制了57%。其次,在野生型和mdr1a(-/-)小鼠中研究了奎尼丁对地高辛处置的影响,在mdr1a(-/-)小鼠中,表达主要地高辛转运P-糖蛋白的基因已被破坏。由于体外数据显示奎尼丁本身是P-糖蛋白底物,因此在mdr1a(-/-)小鼠中降低了奎尼丁剂量,以产生与野生型对照动物相似的血浆浓度。与mdr1a(-/-)小鼠中升高19.5%(P=无显著性差异)相比,奎尼丁使野生型动物的血浆地高辛浓度升高了73.0%(P=0.05)。此外,奎尼丁使野生型动物的地高辛脑浓度升高了73.2%(P=0.05);相比之下,奎尼丁并未使mdr1a(-/-)小鼠的地高辛脑浓度升高,反而使其降低了(-30.7%,P<0.01)。
奎尼丁和地高辛均为P-糖蛋白底物,且奎尼丁在体外是地高辛转运的强效抑制剂。体内数据有力支持了如下假设:在野生型小鼠中,与奎尼丁合用导致血浆地高辛浓度升高的过程中,P-糖蛋白介导的地高辛消除受到抑制起到了重要作用,因此也支持人类中存在类似机制。